FDA approves AstraZeneca’s Imfinzi‑EV regimen for cisplatin‑ineligible bladder cancer and Klygefa for myasthenia gravis
The U.S. Food and Drug Administration granted approval for AstraZeneca’s durvalumab (Imfinzi) combined with en‑fortumab vedotin as a peri‑operative treatment for adult patients with muscle‑invasive bladder cancer who cannot receive cisplatin. The decision is based on the VOLGA Phase III trial, which showed a 49% reduction in disease‑progression risk and a 42% reduction in death risk. On the same day the agency also approved Klygefa (gefurulimab) for adults with generalized myasthenia gravis who are anti‑acetylcholine‑receptor positive, citing the PREVAIL Phase III trial results.
Why it matters
AstraZeneca expects the Imfinzi‑EV regimen to become a new standard of care for cisplatin‑ineligible bladder cancer patients, expanding its oncology portfolio (the company said in the press release)【1】. The Klygefa approval adds a weekly self‑injected rare‑disease therapy, diversifying the company’s specialty‑medicine offerings (pharmtech report)【5】.
Key facts
- 1The FDA approved durvalumab combined with en‑fortumab vedotin as neoadjuvant treatment, followed by durvalumab monotherapy as adjuvant treatment after radical cystectomy for adult patients with muscle‑invasive bladder cancer who are ineligible for or have refused cisplatin‑based chemotherapy. tradingview.com
- 2VOLGA trial interim analysis showed a 49% reduction in risk of disease progression, recurrence, not undergoing surgery or death (event‑free survival hazard ratio 0.51, 95% CI 0.38‑0.67, p < 0.0001). tradingview.com
- 3VOLGA trial also demonstrated a 42% reduction in overall‑survival risk (hazard ratio 0.58, 95% CI 0.40‑0.83, p = 0.0027). tradingview.com
- 4Grade 3‑4 adverse events occurred in 64% of patients receiving the Imfinzi‑EV combination versus 44% in the comparator arm. tradingview.com
- 5Approximately 16,000 patients are expected to be treated for muscle‑invasive bladder cancer in the United States in 2026. tradingview.com
- 6Up to 50% of bladder‑cancer patients are ineligible for cisplatin‑based chemotherapy because of renal impairment or comorbidities. tradingview.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.